TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin has so far been approved for the treatment of CD30 + lymphoproliferative disorders such as classical Hodgkin lymphoma, systemic and primary cutaneous ALCL, MF, AITL and PTCL = NOS.